Novel conjunctivitis drug recommended by FDA

December 17, 2008

Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.

Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.

Besifloxacin, a broad-spectrum fluoroquinolone anti-microbial agent, works by inhibiting inflammation in THP-1 monocytes.

The FDA recommendation is a step towards final approval; if approved, Bausch & Lomb aims to bring besifloxacin to the market next year.